{"id":592438,"date":"2022-03-22T21:15:02","date_gmt":"2022-03-22T21:15:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=592438"},"modified":"2022-03-22T21:15:02","modified_gmt":"2022-03-22T21:15:02","slug":"type-1-diabetes-market-is-expected-to-grow-during-the-forecast-period-20192032-delveinsight-key-players-astrazeneca-sanofilexicon-pharmaceuticals-provention-bio-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/type-1-diabetes-market-is-expected-to-grow-during-the-forecast-period-20192032-delveinsight-key-players-astrazeneca-sanofilexicon-pharmaceuticals-provention-bio-and-others_592438.html","title":{"rendered":"Type 1 Diabetes Market is Expected To Grow During The Forecast Period (2019-2032), DelveInsight | Key Players- AstraZeneca Sanofi\/Lexicon Pharmaceuticals Provention Bio, and Others"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1647933297.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Type 1 Diabetes Market is Expected To Grow During The Forecast Period (2019-2032), DelveInsight | Key Players- AstraZeneca Sanofi\/Lexicon Pharmaceuticals Provention Bio, and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1647933297.jpeg\" alt=\"Type 1 Diabetes Market is Expected To Grow During The Forecast Period (2019-2032), DelveInsight | Key Players- AstraZeneca Sanofi\/Lexicon Pharmaceuticals Provention Bio, and Others\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s&nbsp;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/type-1-diabetes-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Type 1 Diabetes Market<\/a><\/strong>&nbsp;Insights, Epidemiology, and Market Forecast 2032&rdquo; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Type 1 Diabetes Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The&nbsp;Type 1 Diabetes market report&nbsp;covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers &amp; barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Type 1 Diabetes: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Diabetes is a chronic metabolic condition characterized by high or low blood glucose (or blood sugar) levels, leading to significant damage to the heart, blood vessels, eyes, kidneys, and nerves over time. The rationale behind developing diabetes incorporates two factors: insufficient insulin production (produced by the pancreas and reduced blood glucose) or unsatisfactory cell response to insulin action.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get access to a free copy of our latest sample report @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-1-diabetes-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">https:\/\/www.delveinsight.com\/sample-request\/type-1-diabetes-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the&nbsp;Type 1 Diabetes Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>According to the National Diabetes Statistics Report (2020), 34.2 million people in the United States have diabetes in 2018, accounting for 10.5% of the total population.<\/li>\n<li>According to a Secondary search Type 2 Diabetes is more prevalent than Type 1 diabetes.<\/li>\n<li>Type 1 diabetes may affect anybody at any age, although it impacts children and adolescents the most commonly. Over one million children and adolescents under the age of 20 have type 1 diabetes, according to the International Diabetes Federation (IDF).<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/type-1-diabetes-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Type 1 Diabetes Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">Type 1 Diabetes market size&nbsp;is anticipated to increase during the study period owing to the increasing incident population and rising awareness of Type 1 Diabetes in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period.<\/p>\n<p style=\"text-align: justify;\">The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Type 1 Diabetes market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers &amp; barriers, unmet needs, and emerging technologies.<\/p>\n<p style=\"text-align: justify;\">The report gives a thorough detail of the&nbsp;Type 1 Diabetes market&nbsp;trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/type-1-diabetes-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Type 1 Diabetes Market<\/a>&nbsp;Insights<\/strong><\/p>\n<p style=\"text-align: justify;\">People with type 1 diabetes need to follow a different type of plan. A treatment plan, also called a diabetes management plan, helps people to manage their diabetes and stay healthy and active. Everyone&rsquo;s plan is different, and is based upon a person&rsquo;s health needs and the suggestions of the diabetes health care team. The goal of the treatment is to keep your blood sugar level as close to normal as possible to delay or prevent complications. Generally, the goal is to keep the daytime blood sugar levels before meals between 80 and 130 mg\/dL (4.44 to 7.2 mmol\/L) and the after-meal numbers no higher than 180 mg\/dL (10 mmol\/L) two hours after eating.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Type 1 Diabetes Treatment Market<\/strong><\/p>\n<p style=\"text-align: justify;\">Type 1 diabetes arises in response to the complete inability of the pancreas to produce this essential hormone, you need to provide your body with supplemental insulin. Having enough insulin is critical because this hormone is responsible for helping to regulate your blood sugar and keep it in a healthy range&mdash;not too high (hyperglycemia) and not too low (hypoglycemia). It is advised to take insulin several times a day, including the time before and after the meal. Several types of insulin are available. Each type starts to work at a different speed, known as &ldquo;onset,&rdquo; and its effects last a different length of time, known as &ldquo;duration.&rdquo; Most types of insulin reach a peak, which is when they have the strongest effect.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Type 1 Diabetes&nbsp;Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section covers insights about the historical and current Type 1 Diabetes patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Type 1 Diabetes Market&nbsp;Drugs &amp; Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the&nbsp;Type 1 Diabetes market&nbsp;or expected to get launched in the market during the study period. The analysis covers Type 1 Diabetes market uptake by drugs; patient uptake by therapies; and sales of each drug.<\/p>\n<p style=\"text-align: justify;\">Report&rsquo;s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Type 1 Diabetes Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Type 1 Diabetes Emerging Therapy Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">The Type 1 Diabetes market is anticipated to be driven in the coming years due to the rise in novel drugs and therapies and increased healthcare spending across the world. The high prevalence of the disease and participation of the key players like, Provention Bio, Oramed and Tolerion, etc., will influence the market dynamics.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Type 1 Diabetes Companies&nbsp;includes-<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>AstraZeneca<\/li>\n<li>Sanofi\/Lexicon Pharmaceuticals<\/li>\n<li>Provention Bio<\/li>\n<li>Oramed, and others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Type 1 Diabetes Drugs&nbsp;includes-<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>ORMD-0801<\/li>\n<li>Teplizumab<\/li>\n<li>Sotagliflozin<\/li>\n<li>Forxiga, and others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Type 1 Diabetes Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Rise in Insulin consumption as the number of diabetic patients increases<\/li>\n<li>Increase in R&amp;D<\/li>\n<li>Uptake of novel ultra-rapid-acting and ultra-long-acting insulin analogs.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Type 1 Diabetes Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Entry of Biosimilars<\/li>\n<li>High treatment and diagnosis Cost<\/li>\n<li>Inadequate reimbursement policies<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Read Full Research Report @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-1-diabetes-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">https:\/\/www.delveinsight.com\/sample-request\/type-1-diabetes-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of content<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Key Insights<\/li>\n<li>Executive Summary<\/li>\n<li>Competitive Intelligence Analysis<\/li>\n<li>Market Overview at a Glance<\/li>\n<li>Disease Background and Overview<\/li>\n<li>Patient Journey<\/li>\n<li>Epidemiology and Patient Population<\/li>\n<li>Treatment Algorithm, Current Treatment, and Medical Practices<\/li>\n<li>Unmet Needs<\/li>\n<li>Key Endpoints of Type 1 Diabetes Treatment<\/li>\n<li>Marketed Products<\/li>\n<li>Emerging Therapies<\/li>\n<li>Seven Major Market Analysis<\/li>\n<li>Attribute analysis<\/li>\n<li>7MM: Market Outlook<\/li>\n<li>Access and Reimbursement Overview<\/li>\n<li>KOL Views<\/li>\n<li>Market Drivers<\/li>\n<li>Market Barriers<\/li>\n<li>Appendix<\/li>\n<li>DelveInsight Capabilities<\/li>\n<li>Disclaimer<\/li>\n<li>About DelveInsight<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a&nbsp;Business Consulting Services&nbsp;and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations,&nbsp;Competitive Intelligence, Competitive Landscaping, and&nbsp;Mergers &amp; Acquisitions.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=type-1-diabetes-market-is-expected-to-grow-during-the-forecast-period-20192032-delveinsight-key-players-astrazeneca-sanofilexicon-pharmaceuticals-provention-bio-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=type-1-diabetes-market-is-expected-to-grow-during-the-forecast-period-20192032-delveinsight-key-players-astrazeneca-sanofilexicon-pharmaceuticals-provention-bio-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s&nbsp;Type 1 Diabetes Market&nbsp;Insights, Epidemiology, and Market Forecast 2032&rdquo; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Type 1 Diabetes Market Size and Share in the 7MM (i.e. the United States, EU5 &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/type-1-diabetes-market-is-expected-to-grow-during-the-forecast-period-20192032-delveinsight-key-players-astrazeneca-sanofilexicon-pharmaceuticals-provention-bio-and-others_592438.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,423,413],"tags":[],"class_list":["post-592438","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/592438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=592438"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/592438\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=592438"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=592438"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=592438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}